Finder makes money from featured partners, but editorial opinions are our own.

How to buy Clinuvel Pharmaceuticals (CUV) shares in Australia

Learn how to easily invest in Clinuvel Pharmaceuticals shares.

Clinuvel Pharmaceuticals is a biotechnology business based in Australia. Clinuvel Pharmaceuticals shares (CUV) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Clinuvel Pharmaceuticals has a trailing 12-month revenue of around $78.3 million. If you're looking to buy shares, check out the steps below.

How to buy shares in Clinuvel Pharmaceuticals

To buy shares listed in Australia such as Clinuvel Pharmaceuticals, you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose. Then follow these steps.

  1. Open and fund your brokerage account.
    Complete an application with your personal and financial details, including your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  2. Search for Clinuvel Pharmaceuticals.
    Find the share by name or ticker symbol: CUV. Research its history to confirm it's a solid investment against your financial goals.
  3. Purchase now or later.
    Buy today with a market order or use a limit order to delay your purchase until Clinuvel Pharmaceuticals reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
  4. Decide on how many to buy.
    At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  5. Check on your investment.
    Congratulations, you own a part of Clinuvel Pharmaceuticals. Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.

Clinuvel Pharmaceuticals stock price (ASX:CUV)

Use our graph to track the performance of CUV stocks over time.

Clinuvel Pharmaceuticals shares at a glance

Information last updated 2024-02-21.
52-week range$13.97 - $25.6093
50-day moving average $15.9356
200-day moving average $17.0663
Target price$28.81
PE ratio 27.6102
Dividend yield $0.05 (0.31%)
Earnings per share (TTM) $0.59

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
1 - 7 of 33
Name Product Standard brokerage fee Inactivity fee Asset class
Finder AwardExclusive
US$10 per month if there’s been no log-in for 12 months
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 12 months of investment tracking app Delta PRO for free when you fund your eToro account (T&Cs apply).
CFD service. Capital at risk.
Join the world's biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
ASX shares, Global shares, US shares, UK shares, ETFs
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian and international shares, plus get access to 24-hour customer support.
Moomoo Share Trading
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get an additional 30 days on top of the regular brokerage-free period for new accounts. T&Cs apply.
Trade shares on the ASX, the US markets and buy ETFs with Moomoo. Plus join a community over 20 million investors.
CMC Invest
Finder Award
CMC Invest
ASX shares, Global shares, Options trading, US shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 35,000 products, including shares, ETFs and managed funds, with access to 15 major global and Australian stock exchanges. Plus, buy Aussie shares for $0 brokerage up to $1,000. (Limited to one buy order per stock per trading day).
ASX shares, Options trading, US shares, ETFs
Fund your account with over $200 and complete 1 buy trade to earn $50 in free shares. Fund over $10,000 for up to $1,200 in trading vouchers, or over $100,000 for up to $4,000 in vouchers. Plus, enjoy 5.3% p.a. yield on US cash accounts with Moneybull (T&Cs apply).
Trade ASX and US stocks and US options, plus gain access to inbuilt news platforms and educational resources. You can also start trading for less with fractional shares.
Tiger Brokers
Tiger Brokers
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 10 brokerage-free trades for the US or ASX market for the first 180 days and US$50 fractional shares when you deposit at least US$500. Plus, all new customers get 1 free trade per month for the first 12 months. Offer valid until February 29, 2024 (T&Cs apply).
Get one brokerage-free trade per month for the first 12 months for US or ASX markets. T&Cs apply.
Saxo Invested
ASX shares, Global shares, Options trading, US shares, ETFs
Access 22,000+ stocks on 50+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.

Is it a good time to buy Clinuvel Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Clinuvel Pharmaceuticals price performance over time

Historical closes compared with the last close of A$16.29

1 week (2024-02-14) 3.76%
1 month (2024-01-19) 4.42%
3 months (2023-11-21) -1.93%
6 months (2023-08-21) -22.43%
1 year (2023-02-21) -31.47%
2 years (2022-02-21) -25.38%
3 years (2021-02-19) -19.36%
5 years (2019-02-21) -32.04%

Is Clinuvel Pharmaceuticals under- or over-valued?

Valuing Clinuvel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clinuvel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Clinuvel Pharmaceuticals's P/E ratio

Clinuvel Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 28x. In other words, Clinuvel Pharmaceuticals shares trade at around 28x recent earnings.

That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Clinuvel Pharmaceuticals's EBITDA

Clinuvel Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $44.5 million (£0.0 million).

The EBITDA is a measure of a Clinuvel Pharmaceuticals's overall financial performance and is widely used to measure stock profitability.

Clinuvel Pharmaceuticals financials

Revenue TTM $78.3 million
Operating margin TTM 61%
Gross profit TTM $70.8 million
Return on assets TTM 16.33%
Return on equity TTM 21.09%
Profit margin 39.08%
Book value 3.332
Market capitalisation $816.6 million

TTM: trailing 12 months

Clinuvel Pharmaceuticals share dividends


Dividend payout ratio: 6.77% of net profits

Recently Clinuvel Pharmaceuticals has paid out, on average, around 6.77% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.31% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Clinuvel Pharmaceuticals shareholders could enjoy a 0.31% return on their shares, in the form of dividend payments. In Clinuvel Pharmaceuticals's case, that would currently equate to about A$0.05 per share.

While Clinuvel Pharmaceuticals's payout ratio might seem low, this can signify that Clinuvel Pharmaceuticals is investing more in its future growth.

The latest dividend was paid out to all shareholders who bought their shares by 4 September 2023 (the "ex-dividend date").

Have Clinuvel Pharmaceuticals's shares ever split?

Clinuvel Pharmaceuticals's shares were split on a 1:10 basis on 11 November 2010. So if you had owned 10 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Clinuvel Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Clinuvel Pharmaceuticals shares which in turn could have impacted Clinuvel Pharmaceuticals's share price.

Clinuvel Pharmaceuticals share price volatility

Over the last 12 months, Clinuvel Pharmaceuticals's shares have ranged in value from as little as $13.97 up to $25.6093. A popular way to gauge a stock's volatility is its "beta".

CUV.AU volatility(beta: 0.77)Avg. volatility(beta: 1.00)LowHigh

Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Clinuvel Pharmaceuticals's is 0.772. This would suggest that Clinuvel Pharmaceuticals's shares are less volatile than average (for this exchange).

Clinuvel Pharmaceuticals overview

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Frequently asked questions

  1. EOD price data and company information for Clinuvel Pharmaceuticals accessed 21 Feb 2024
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and 6. Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site